New combo eye drop could simplify Post-Cataract care
NCT ID NCT07305987
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests a new eye drop called PRO-232, which combines an antibiotic (moxifloxacin) and a steroid (dexamethasone) in one bottle. It aims to see if this single drop works as well as using two separate drops to prevent infection and control inflammation after cataract surgery. The study will enroll 134 adults and measure how well the eye heals and any side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PRO-232 (moxifloxacin and dexamethasone) ophthalmic solution
What this could lead to
If it works, this could offer a simpler, single-bottle eye drop to prevent infection and control inflammation after cataract surgery, replacing the need for two separate drops.
What could go wrong
This is a Phase 3 trial, but it's relatively small (134 people) and compares to existing treatments, so any advantage may be modest. Side effects from the antibiotics or steroids are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CATARACT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
RGH Integra
RECRUITINGPuebla City, Puebla, 72180, Mexico
-
Retina Center
RECRUITINGTijuana, Estado de Baja California, 22010, Mexico